Gastrooesophageal Cancer Clinical Trial
Official title:
Open-label Study of Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Participants Previously Treated for Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma With CEACAM5-positive Tumors
Primary Objectives: Part 1: to confirm the recommended tusamitamab ravtansine loading dose Q2W in combination with ramucirumab in advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma population Part 2: to assess the antitumor activity of tusamitamab ravtansine loading dose Q2W in combination with ramucirumab in advanced gastric or GEJ adenocarcinoma Secondary Objectives: - To assess safety - To assess durability - To assess progression-free survival (PFS) - To assess the disease control rate (DCR) - To assess the pharmacokinetics (PK) - To assess the immunogenicity
34 weeks (up to 4 weeks for screening, a median of 18 weeks for treatment, and a median of 12 weeks for end-of-treatment assessments and the safety follow-up visit). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01135849 -
B-Receptor Signaling in Cardiomyopathy
|
N/A | |
| Withdrawn |
NCT02274012 -
Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment
|
Phase 2 | |
| Completed |
NCT01980394 -
Esophageal Stump Washout
|
N/A | |
| Terminated |
NCT01365130 -
Chemotherapy for Patients With Gastroesophageal Cancers Who Have Progressed After One Prior Chemo Regimen
|
Phase 2 | |
| Recruiting |
NCT02884453 -
Proof-of-concept Study of Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma
|
Phase 2 | |
| Completed |
NCT03416244 -
A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer
|
Phase 2 | |
| Terminated |
NCT00767234 -
Permission to Collect Blood Over Time for Research
|
N/A | |
| Recruiting |
NCT05965479 -
Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer
|
Phase 2 |